Longfellow Investment Management Co. LLC Purchases Shares of 6,053 Abbott Laboratories $ABT

Longfellow Investment Management Co. LLC purchased a new position in Abbott Laboratories (NYSE:ABT) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,053 shares of the healthcare product maker’s stock, valued at approximately $811,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABT. Norges Bank purchased a new stake in Abbott Laboratories during the 2nd quarter worth about $3,026,180,000. Laurel Wealth Advisors LLC grew its position in shares of Abbott Laboratories by 13,347.0% during the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after buying an additional 6,011,891 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.8% during the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares during the period. First Trust Advisors LP raised its holdings in Abbott Laboratories by 180.7% in the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after acquiring an additional 1,972,097 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Abbott Laboratories by 3.8% in the second quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after acquiring an additional 1,390,554 shares during the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Trading Down 1.9%

ABT opened at $110.97 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. Abbott Laboratories has a 52 week low of $105.27 and a 52 week high of $139.15. The business’s 50 day moving average is $116.39 and its two-hundred day moving average is $124.82. The firm has a market cap of $192.83 billion, a price-to-earnings ratio of 29.83, a price-to-earnings-growth ratio of 1.80 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period last year, the firm posted $1.34 earnings per share. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, research analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ABT shares. Sanford C. Bernstein reduced their price objective on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Citigroup dropped their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Raymond James Financial decreased their price target on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, Argus decreased their target price on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $137.05.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, EVP Elizabeth C. Cushman sold 263 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $30,397.54. Following the completion of the sale, the executive vice president directly owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. This trade represents a 0.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP John A. Jr. Mccoy sold 585 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president directly owned 24,628 shares in the company, valued at approximately $2,846,504.24. The trade was a 2.32% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.